Chronic Respiratory Disease

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conway, S P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conway, S P
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Chronic Respiratory Disease, Vol. 2, No. 1, 35-41 (2005)
DOI: 10.1191/1479972305cd045rs


Reviews

Nebulized antibiotic therapy: the evidence

S P Conway

St James' Hospital, CF Unit, Children's Day Hospital, Beckett Street, Leeds, LS9 7TF, UKsteven.conway{at}leedsth.nhs.uk

The main indications for nebulized antibiotic use are as maintenance therapy for patients with chronic Pseudomonas aeruginosa infection and in treatment protocols aimed at eradicating early P. aeruginosa infection. Daily nebulized antibiotic therapy has been used extensively in Europe for the last 25 years and recently in North America following the introduction of tobramycin solution for inhalation (TSI). The antibiotic is delivered directly to the site of infection, maximizing its efficacy and reducing its potential for toxicity. The efficacy of nebulized antibiotic therapy has been confirmed by meta–analyses of early studies which usually involved only small numbers of patients, and recently by large scale randomized control trials. These studies have shown that regular aerosolized antibiotic treatment results in improved respiratory function, less hospital admissions and respiratory exacerbations, and a significant reduction in the load of P. aeruginosa respiratory tract infection. Concerns about increasing bacterial resistance do not yet seem to have had any clinical impact. Successful eradication of early P. aeruginosa infection has been reported with nebulized colistin (in combination with oral ciprofloxacin), tobramycin and TSI. No advantage has been shown in studies comparing nebulized and intravenous antibiotics versus intravenous antibiotics alone in the treatment of acute respiratory exacerbations. Inhalation of antibiotics may provoke bronchospasm and patients should be assessed before and after treatment prior to continuing long–term therapy at home.

Key Words: cystic fibrosis • nebulized antibiotics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?